These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25060671)

  • 1. ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.
    Shah RR; Morganroth J; Kleiman RB
    Br J Clin Pharmacol; 2015 Mar; 79(3):456-64. PubMed ID: 25060671
    [No Abstract]   [Full Text] [Related]  

  • 2. ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.
    Shah RR; Morganroth J
    Br J Clin Pharmacol; 2013 Apr; 75(4):959-65. PubMed ID: 22905923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay sensitivity in "Hybrid thorough QT/QTc (TQT)" study.
    Huang DP; Chen J; Dang Q; Tsong Y
    J Biopharm Stat; 2019; 29(2):378-384. PubMed ID: 30346877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.
    Garnett CE; Beasley N; Bhattaram VA; Jadhav PR; Madabushi R; Stockbridge N; Tornøe CW; Wang Y; Zhu H; Gobburu JV
    J Clin Pharmacol; 2008 Jan; 48(1):13-8. PubMed ID: 18094216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
    Salvi V; Karnad DR; Panicker GK; Kothari S
    Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculations in thorough QT studies.
    Zhang L; Dmitrienko A; Luta G
    J Biopharm Stat; 2008; 18(3):468-82. PubMed ID: 18470756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates.
    Bloomfield D; Krishna R
    J Clin Pharmacol; 2008 Jan; 48(1):6-8. PubMed ID: 18094214
    [No Abstract]   [Full Text] [Related]  

  • 13. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A perspective on the use of concentration-QT modeling in drug development.
    Russell T; Riley SP; Cook JA; Lalonde RL
    J Clin Pharmacol; 2008 Jan; 48(1):9-12. PubMed ID: 18094215
    [No Abstract]   [Full Text] [Related]  

  • 15. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
    Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
    Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacing the thorough QT study: reflections of a baby in the bath water.
    Kleiman RB; Shah RR; Morganroth J
    Br J Clin Pharmacol; 2014 Aug; 78(2):195-201. PubMed ID: 24286381
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed effects in the exposure-response analysis of clinical QTc trials.
    Glomb P; Ring A
    J Biopharm Stat; 2012; 22(2):387-400. PubMed ID: 22251181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities.
    Camm AJ
    Fundam Clin Pharmacol; 2002 Apr; 16(2):141-5. PubMed ID: 12031066
    [No Abstract]   [Full Text] [Related]  

  • 19. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.
    Darpo B; Garnett C; Keirns J; Stockbridge N
    Drug Saf; 2015 Sep; 38(9):773-80. PubMed ID: 26162419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.